Product Description
Cibinetide significantly increased small nerve fiber abundance in the cornea and skin, consistent with a disease modifying effect. (Sourced from: https://iovs.arvojournals.org/article.aspx?articleid=2625918)
Mechanisms of Action: SRI Inhibitor
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: Injection
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: LUMC
Company Location: Europe
Company Founding Year: 1996
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Sarcoidosis|Depressive Disorder|Small Fiber Neuropathy|Macular Edema|Type 2 Diabetes|Prediabetic State|Complex Regional Pain Syndromes|Arthritis, Rheumatoid|Glucose Intolerance|Inflammation|Prediabetes|Insulin Resistance|Neuropathic Pain
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2015-001940-12 |
The use of ARA 290 for the treatment of DMO (ARA 290-DMO) v1 | P2 |
Terminated |
Macular Edema |
2017-08-29 |
2022-03-13 |
Treatments |
|
NCT06626971 |
ARA290DMO | P2 |
Terminated |
Macular Edema |
2017-05-12 |
2024-10-05 |
Primary Endpoints|Treatments |
|
2013-003016-45 |
DOSARA | P2 |
Completed |
Small Fiber Neuropathy |
2015-02-02 |
2022-03-13 |
Treatments |
|
NCT02039687 |
APCP-112 | P2 |
Completed |
Sarcoidosis |
2015-01-01 |
2019-03-20 |
Treatments |
|
2012-003207-35 |
ARA290inT2D | P2 |
Completed |
Prediabetes|Type 2 Diabetes |
2014-12-02 |
2022-03-13 |
Treatments |
|
NCT01933529 |
APCP-115 | P2 |
Unknown status |
Insulin Resistance|Type 2 Diabetes|Glucose Intolerance|Prediabetic State |
2014-06-01 |
2019-03-19 |
Treatments |
|
2012-005590-32 |
ARAND | P2 |
Active, not recruiting |
Type 2 Diabetes |
2013-11-20 |
2022-03-13 |
Treatments |
|
2012-003688-24 |
CRPSARA | P2 |
Active, not recruiting |
Complex Regional Pain Syndromes |
2013-03-12 |
2022-03-13 |
Treatments |
|
NCT02070783 |
CONEARA | P2 |
Completed |
Depressive Disorder |
2013-02-01 |
2019-03-20 |
Treatments |
|
2010-021518-45 |
2010-021518-45 | P2 |
Active, not recruiting |
Neuropathic Pain |
2012-07-06 |
2022-03-13 |
Treatments |
|
2010-023469-22 |
ARA 290 in ARA | P2 |
Active, not recruiting |
Arthritis, Rheumatoid |
2012-03-09 |
2022-03-13 |
Treatments |
|
2010-024364-18 |
Cognitive and neural effects of ARA290 | P2 |
Active, not recruiting |
Depressive Disorder |
2011-10-12 |
2022-03-13 |
Treatments |
|
2010-018584-41 |
2010-018584-41 | P2 |
Active, not recruiting |
Inflammation |
2011-07-23 |
2025-07-05 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
08/01/2025 |
News Article |
Public advisory - Unauthorized injectable peptide drugs seized and sold by Canada Peptide may pose serious health risks |
|
04/01/2025 |
News Article |
Public advisory - Unauthorized injectable peptide drugs seized from Optimum Wellness Centre in Calgary, Alberta may pose serious health risks |
|
07/21/2020 |
News Article |
Innate Repair Activator Cibinetide Shows Potential for Efficacy in Diabetic Macular Edema |
|
11/21/2019 |
News Article |
Araim Pharmaceuticals Selects Ferry Breedveld as Acting CEO |